Unknown

Dataset Information

0

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.

ABSTRACT:

SUBMITTER: Malissen N 

PROVIDER: S-EPMC8352671 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.

Malissen Nausicaa N   Ninove Laetitia L   de Lamballerie Xavier X   André Nicolas N   Gaudy-Marqueste Caroline C  

European journal of cancer (Oxford, England : 1990) 20210810

Similar Datasets

Unknown Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
| S-EPMC9472569 | biostudies-literature
Unknown Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
| S-EPMC8174030 | biostudies-literature
Unknown Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up.
| S-EPMC9745767 | biostudies-literature
Unknown Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults.
| S-EPMC10581992 | biostudies-literature
Unknown Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics.
| S-EPMC9485492 | biostudies-literature
Unknown Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
| S-EPMC8078907 | biostudies-literature
Unknown Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.
| S-EPMC3417327 | biostudies-literature
Unknown Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
| S-EPMC10893482 | biostudies-literature
Unknown Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.
| S-EPMC12339817 | biostudies-literature
Unknown Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
| S-EPMC9084623 | biostudies-literature